sponsored
PatientsVille.com Logo

PatientsVille

Primitive Medical Research Studies

Up-to-date List of Primitive Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Primitive Medical Research Studies

Rank Status Study
1 Recruiting Peripheral Blood Stem Cells Obtained From Normal Volunteers for Studying Retroviral Vector Mediated Gene Transfer Into Primitive Hematopoietic Cells and Vector Mediated Transgene Expression in Mature Hematopoietic Lineages
Condition: Healthy Volunteers
Interventions: Drug: G-CSF;   Procedure: Stem Cell Apheresis
Outcome Measure: To compare the relative efficiencies of lentiviral and foamy virus vectors in transducing Primitive hematopoietic cells mobilized into peripheral blood by cytokine administration.
2 Recruiting Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Conditions: Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: temozolomide;   Drug: irinotecan hydrochloride;   Biological: bevacizumab
Outcome Measures: Overall survival for each treatment arm;   Response rate for each treatment arm;   Event-free survival
3 Unknown  Low-Dose Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor or Medulloblastoma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: lomustine;   Drug: vincristine sulfate
Outcome Measures: Relapse-free survival;   Survival;   Exoprimary-site relapse rate;   Time to first recurrence;   Degree of neurocognitive post-treatment decline or dysfunction as measured by an IQ test at baseline and after 1, 2, and 3 years;   Degree of hearing loss;   Decline in growth, sexual maturation, or need for hormone replacement;   Adverse events
4 Recruiting Peripheral Primitive Fibromatosis
Condition: Peripheral Primitive Fibromatosis
Intervention: Other: MRI
Outcome Measures: Progression Free Survival;   Functional result
5 Recruiting Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
Conditions: Medulloblastoma;   Neuroectodermal Tumor
Interventions: Biological: TTRNA-xALT;   Biological: TTRNA-DCs
Outcome Measure: Percentage of Subject with Progression-Free Survival
6 Unknown  Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years
Condition: Metastatic, Cerebral Primitive Neuroectodermal Tumors
Intervention: Drug: Chemotherapy (carboplatin, etoposide, thiotepa)
Outcome Measure:
7 Unknown  High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood
Conditions: Medulloblastoma;   Brain Tumors;   Neuroectodermal Tumors, Primitive
Intervention: Drug: Etoposide, carboplatin, melphalan, cisplatin, thiotepa
Outcome Measures: Response of medulloblastoma metastases to the chemotherapy regimen in children less than 5 years of age;   Progression-free survival of children less than 10 years of age with brain PNET;   Progression-free survival of children less than 5 years of age with metastatic medulloblastoma;   Toxicity;   Long term sequelae
8 Recruiting Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Conditions: Adult Supratentorial Primitive Neuroectodermal Tumor (PNET);   Childhood Supratentorial Primitive Neuroectodermal Tumor;   Ewing Sarcoma of Bone;   Extraosseous Ewing Sarcoma;   Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Peripheral Primitive Neuroectodermal Tumor of the Kidney;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: ifosfamide;   Drug: etoposide;   Drug: topotecan hydrochloride;   Other: laboratory biomarker analysis
Outcome Measures: EFS;   Overall survival;   Relative risk for death;   Histological response, in terms of event free survival after local control in patients who received local control therapy;   Positron emission tomography (PET)-determined response, in terms of event free survival after local control;   Probabilities of identifying tumors of at least 200 ml;   Extent of tumor necrosis according to the necrosis grading criteria in patients who have surgical resection of tumor;   Radiological response of soft tissue component of mass by PET;   Differences associated with local control modality on risk for EFS event, according to surgery only v. radiation therapy only v. surgery and radiation therapy;   Number and proportion of patients who experience any grade 2 or higher musculoskeletal event (ME), or surgery required to treat a complication of local therapy;   Proportion of patients who have tumor present at the margin of resection on risk for EFS event in patients undergoing surgery
9 Recruiting Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma
Conditions: Adult Supratentorial Primitive Neuroectodermal Tumor (PNET);   Ewing Sarcoma of Bone;   Extraosseous Ewing Sarcoma;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: etoposide;   Drug: ifosfamide;   Radiation: intensity-modulated radiation therapy;   Drug: topotecan hydrochloride;   Drug: busulfan;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: autologous bone marrow transplantation
Outcome Measures: Percentage of patients who experience grade 4-5 non-hematologic toxicities assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;   Overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST);   Progression-free survival (PFS);   Overall survival (OS);   Non-relapse mortality (NRM)
10 Recruiting Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
Conditions: Askin Tumor;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Intervention: Other: laboratory biomarker analysis
Outcome Measure: Banking of biological specimens, including associated demographic and clinical data
11 Recruiting Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
Conditions: Acoustic Schwannoma;   Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Meningioma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Choroid Plexus Tumor;   Adult Craniopharyngioma;   Adult Diffuse Astrocytoma;   Adult Ependymoblastoma;   Adult Ependymoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Grade I Meningioma;   Adult Grade II Meningioma;   Adult Medulloblastoma;   Adult Meningeal Hemangiopericytoma;   Adult Mixed Glioma;   Adult Myxopapillary Ependymoma;   Adult Oligodendroglioma;   Adult Papillary Meningioma;   Adult Pilocytic Astrocytoma;   Adult Pineal Gland Astrocytoma;   Adult Pineoblastoma;   Adult Pineocytoma;   Adult Subependymal Giant Cell Astrocytoma;   Adult Subependymoma;   Adult Supratentorial Primitive Neuroectodermal Tumor (PNET);   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebellar Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Medulloepithelioma;   Childhood Supratentorial Ependymoma;   Meningeal Melanocytoma;   Newly Diagnosed Childhood Ependymoma;   Recurrent Adult Brain Tumor;   Recurrent Childhood Anaplastic Astrocytoma;   Recurrent Childhood Anaplastic Oligoastrocytoma;   Recurrent Childhood Anaplastic Oligodendroglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Diffuse Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Fibrillary Astrocytoma;   Recurrent Childhood Gemistocytic Astrocytoma;   Recurrent Childhood Giant Cell Glioblastoma;   Recurrent Childhood Glioblastoma;   Recurrent Childhood Gliomatosis Cerebri;   Recurrent Childhood Gliosarcoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Oligoastrocytoma;   Recurrent Childhood Oligodendroglioma;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Pilomyxoid Astrocytoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Pleomorphic Xanthoastrocytoma;   Recurrent Childhood Protoplasmic Astrocytoma;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Untreated Childhood Anaplastic Astrocytoma;   Untreated Childhood Anaplastic Oligodendroglioma;   Untreated Childhood Brain Stem Glioma;   Untreated Childhood Cerebellar Astrocytoma;   Untreated Childhood Cerebral Astrocytoma;   Untreated Childhood Diffuse Astrocytoma;   Untreated Childhood Fibrillary Astrocytoma;   Untreated Childhood Gemistocytic Astrocytoma;   Untreated Childhood Giant Cell Glioblastoma;   Untreated Childhood Glioblastoma;   Untreated Childhood Gliomatosis Cerebri;   Untreated Childhood Gliosarcoma;   Untreated Childhood Medulloblastoma;   Untreated Childhood Oligoastrocytoma;   Untreated Childhood Oligodendroglioma;   Untreated Childhood Pilocytic Astrocytoma;   Untreated Childhood Pilomyxoid Astrocytoma;   Untreated Childhood Pineoblastoma;   Untreated Childhood Pleomorphic Xanthoastrocytoma;   Untreated Childhood Protoplasmic Astrocytoma;   Untreated Childhood Subependymal Giant Cell Astrocytoma;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor;   Untreated Childhood Visual Pathway and Hypothalamic Glioma;   Untreated Childhood Visual Pathway Glioma
Interventions: Radiation: gallium Ga 68-edotreotide;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: laboratory biomarker analysis
Outcome Measures: Change in standardized uptake value (SUV) uptake after gallium Ga 68-edotreotide;   Proportion of discordance and concordance between gallium Ga 68-edotreotide and biopsy
12 Recruiting Local Treatment by Thermic Destruction of Primitive Breast Cancer
Condition: Breast Cancer
Intervention: Procedure: Thermic destruction of tissue by Laser using the Novilase device
Outcome Measures: Effectiveness of laser treatment;   Life quality
13 Recruiting Absorbable Sutures , Non Absorbable Sutures or Biologic Fibrin Glue for Protesic Mesh Fixing in Lichtenstein Technique for Primitive Groin Hernia Repair: a Randomized Prospective Multicentric Trial
Condition: Hernia, Inguinal
Interventions: Procedure: Lichtenstein technique groin hernia repair with mesh. Use of absorbale sutures for mesh fixation;   Procedure: Lichtenstein technique groin hernia repair with mesh. Use of non absorbable sutures for mesh fixation;   Procedure: Lichtenstein technique groin hernia repair with mesh. Use of fibrin biological glue for mesh fixation
Outcome Measures: rate of recurrence;   rate of chronic pain
14 Recruiting Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
Conditions: Desmoplastic Small Round Cell Tumor;   Ewing Sarcoma of Bone or Soft Tissue;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Interventions: Drug: vincristine;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: ifosfamide;   Drug: etoposide;   Drug: temozolomide;   Drug: temsirolimus;   Drug: bevacizumab;   Drug: sorafenib;   Procedure: surgery;   Radiation: radiation
Outcome Measures: Response rate;   Overall Survival;   Progression-free survival;   Time to progression;   Local failure rate
15 Recruiting Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Hemangioendothelioma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Dermatofibrosarcoma Protuberans;   Gastrointestinal Stromal Tumor;   Metastatic Adult Malignant Fibrous Histiocytoma of Bone;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Osteosarcoma;   Ovarian Sarcoma;   Recurrent Adult Malignant Fibrous Histiocytoma of Bone;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Kaposi Sarcoma;   Recurrent Osteosarcoma;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Uterine Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Uterine Sarcoma
Interventions: Drug: vismodegib;   Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Maximum-tolerated dose of gamma-secretase inhibitor RO4929097, defined as the dose level where no more than 1 out of 6 patients experience DLT at the highest dose level below the MAD, graded according to NCI-CTCAE version 4.0 (Phase Ib);   Progression-free survival as defined by RECIST 1.1 (Phase II);   Change in protein levels from pre- and post-treatment biopsies (Phase Ib and II);   Response rate (CR + PR) as assessed by RECIST 1.1 (Phase Ib and II);   Overall survival (Phase II)
16 Recruiting 18F-DOPA-PET in Planning Surgery in Patients With Gliomas
Conditions: Acoustic Schwannoma;   Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Meningioma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Choroid Plexus Tumor;   Adult Craniopharyngioma;   Adult Diffuse Astrocytoma;   Adult Ependymoblastoma;   Adult Ependymoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Grade I Meningioma;   Adult Grade II Meningioma;   Adult Medulloblastoma;   Adult Meningeal Hemangiopericytoma;   Adult Mixed Glioma;   Adult Myxopapillary Ependymoma;   Adult Oligodendroglioma;   Adult Papillary Meningioma;   Adult Pilocytic Astrocytoma;   Adult Pineal Gland Astrocytoma;   Adult Pineoblastoma;   Adult Pineocytoma;   Adult Subependymal Giant Cell Astrocytoma;   Adult Subependymoma;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebellar Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Medulloepithelioma;   Childhood Mixed Glioma;   Childhood Supratentorial Ependymoma;   Meningeal Melanocytoma;   Newly Diagnosed Childhood Ependymoma;   Recurrent Adult Brain Tumor;   Recurrent Childhood Anaplastic Astrocytoma;   Recurrent Childhood Anaplastic Oligoastrocytoma;   Recurrent Childhood Anaplastic Oligodendroglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Diffuse Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Fibrillary Astrocytoma;   Recurrent Childhood Gemistocytic Astrocytoma;   Recurrent Childhood Giant Cell Glioblastoma;   Recurrent Childhood Glioblastoma;   Recurrent Childhood Gliomatosis Cerebri;   Recurrent Childhood Gliosarcoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Oligoastrocytoma;   Recurrent Childhood Oligodendroglioma;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Pilomyxoid Astrocytoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Pleomorphic Xanthoastrocytoma;   Recurrent Childhood Protoplasmic Astrocytoma;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Untreated Childhood Anaplastic Astrocytoma;   Untreated Childhood Anaplastic Oligoastrocytoma;   Untreated Childhood Anaplastic Oligodendroglioma;   Untreated Childhood Brain Stem Glioma;   Untreated Childhood Diffuse Astrocytoma;   Untreated Childhood Fibrillary Astrocytoma;   Untreated Childhood Gemistocytic Astrocytoma;   Untreated Childhood Giant Cell Glioblastoma;   Untreated Childhood Glioblastoma;   Untreated Childhood Gliomatosis Cerebri;   Untreated Childhood Gliosarcoma;   Untreated Childhood Medulloblastoma;   Untreated Childhood Oligoastrocytoma;   Untreated Childhood Oligodendroglioma;   Untreated Childhood Pilocytic Astrocytoma;   Untreated Childhood Pilomyxoid Astrocytoma;   Untreated Childhood Pineoblastoma;   Untreated Childhood Pleomorphic Xanthoastrocytoma;   Untreated Childhood Protoplasmic Astrocytoma;   Untreated Childhood Subependymal Giant Cell Astrocytoma;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor;   Untreated Childhood Visual Pathway and Hypothalamic Glioma;   Untreated Childhood Visual Pathway Glioma
Interventions: Drug: fluorine F 18 fluorodopa;   Procedure: positron emission tomography;   Procedure: computed tomography;   Procedure: diffusion-weighted magnetic resonance imaging;   Procedure: perfusion-weighted magnetic resonance imaging;   Procedure: therapeutic conventional surgery;   Procedure: biopsy;   Other: laboratory biomarker analysis
Outcome Measures: Ratios of maximum tumor standardized uptake value (SUVmax) normalized to mean SUV (SUVmean) of T/N;   MRI contrast enhancement values;   Histologic grade of the specimen defined as HGG, LGG, or non-malignant brain tissue;   Proportion of patients whose maximum 18F-DOPA uptake samples are in agreement with the final diagnostic grade;   Differences in volumes generated from biopsy-validated thresholds evaluated by 18F-DOPA-PET, pMRI, and DTI;   Progression free survival
17 Not yet recruiting Molecular-Guided Therapy for Childhood Cancer
Conditions: Neuroblastoma;   Medulloblastoma;   Glioma;   Ependymoma;   Choroid Plexus Neoplasms;   Craniopharyngioma;   Dysembryoplastic Neuroepithelial Tumor;   Meningioma;   Primitive Neuroectodermal Tumors (PNETs);   Germ Cell Tumors;   Rhabdomyosarcoma;   Non-rhabdomyosarcoma;   Ewings Sarcoma;   Osteosarcoma;   Wilms Tumor;   Renal Cell Carcinoma;   Malignant Rhabdoid Tumor;   Clear Cell Sarcoma;   Liver Tumors
Intervention: Device: Guided Therapy
Outcome Measures: Days to treatment will be used in order to determine feasibility of using tumor samples to assess genomic sequencing using predictive modeling to make real-time treatment decisions for children with relapsed/refractory cancers.;   Number of Participants with Adverse Events as a Measure of Safety;   Overall Response Rate (ORR) of Participants by the presence of radiologically assessable disease by cross-sectional CT or MRI imaging and/or by MIBG or PET scans.;   Duration of response will be objectively documented;   Biology studies to include: genomic analysis of cells pre- and post- treatment, correlation of in vitro response to in vivo response, sub analysis examination of disease types, and biomarker development.;   Progression Free Survival (PFS) interval will be measured by days and compared to the PFS of previous chemotherapy regimens since relapse for each patient.
18 Recruiting WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Conditions: Recurrent Childhood Medulloblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: WEE1 inhibitor MK-1775;   Drug: irinotecan hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis
Outcome Measures: MTD defined as the maximum doses of WEE1 inhibitor MK-1775 and irinotecan hydrochloride at which fewer than one-third of patients experience dose limiting toxicities when receiving this combination;   Pharmacokinetic (PK) parameters of WEE1 inhibitor MK-1775 in terms of systemic exposure;   PK parameters of WEE1 inhibitor MK-1775 in terms of drug clearance;   Response rate according to Response Evaluation Criteria in Solid Tumors;   Change in phosphorylated-cyclin-dependent kinase 1 (p-CDK1) levels;   Predictive biomarkers of WEE1 inhibitor MK-1775 sensitivity
19 Not yet recruiting Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
Conditions: Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Extracranial Germ Cell Tumor;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebellar Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Malignant Ovarian Germ Cell Tumor;   Childhood Malignant Testicular Germ Cell Tumor;   Childhood Medulloepithelioma;   Childhood Supratentorial Ependymoma;   Childhood Teratoma;   Recurrent Childhood Anaplastic Astrocytoma;   Recurrent Childhood Anaplastic Oligoastrocytoma;   Recurrent Childhood Anaplastic Oligodendroglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Diffuse Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Fibrillary Astrocytoma;   Recurrent Childhood Gemistocytic Astrocytoma;   Recurrent Childhood Giant Cell Glioblastoma;   Recurrent Childhood Glioblastoma;   Recurrent Childhood Gliomatosis Cerebri;   Recurrent Childhood Gliosarcoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Oligoastrocytoma;   Recurrent Childhood Oligodendroglioma;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Pilomyxoid Astrocytoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Pleomorphic Xanthoastrocytoma;   Recurrent Childhood Protoplasmic Astrocytoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Retinoblastoma;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: etoposide;   Drug: ifosfamide;   Drug: carboplatin;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Drug: cyclophosphamide;   Drug: cisplatin;   Biological: filgrastim;   Other: laboratory biomarker analysis
Outcome Measures: Duration (days) of ANC less than 500/uL;   Days to ANC greater than or equal to 1,000/uL from the start of chemotherapy;   Days to transfusion unsupported platelet count greater than or equal to 75,000/uL from the start of chemotherapy;   Incidence of febrile neutropenia;   Incidence of hospitalization;   Number of platelet transfusions per chemotherapy cycle;   Days of filgrastim administration;   Incidence of filgrastim related pain;   Duration of filgrastim related pain;   Incidence of bacteremia;   Percentage of progenitor cells in peripheral blood
20 Unknown  Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Conditions: Brain and Central Nervous System Tumors;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neuroblastoma;   Pheochromocytoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Radiation: yttrium Y 90-edotreotide
Outcome Measure:

These studies may lead to new treatments and are adding insight into Primitive etiology and treatment.

A major focus of Primitive research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Primitive